Useful Reading

Las Vegas SUN:
Horsford: Prescription Drug Affordability Not a Partisan Issue

Some of the bills Rep. Steve Horsford and other Democrats have backed — including measures to expand access to dental care and cap prescription drug costs — are headed to the House floor after passing through committee mark-up last week.

List Prices for Medicare Part D Drugs Exceeded Inflation in 2016, 2017, Analysis Says

List price increases for many Medicare Part D drugs—both brands and generics—exceeded inflation in 2016 and 2017, in some cases by a substantial margin, according to a recent analysis from the Kaiser Family Foundation.

Report: Prescription Drug Prices Climb Nearly 26% in 3 Years

Drug pricing transparency has long been an area of focus for consumers and policymakers, with numerous studies highlighting the inequity in drug spending across various disease states as well as a recent substantial rise in out-of-pocket costs.

Can Washington Deliver on Drug Costs Amid Impeachment Probe?

Major legislation to reduce prescription drug costs for millions of people may get sidelined now that House Democrats have begun an impeachment inquiry of President Donald Trump.

Wall Street Journal: Drugmakers, Worried About Losing Pricing Power, Are Lobbying Hard

Pharmaceutical industry attacks proposals in Washington that could cut deeply into companies’ sales.

Bloomberg: Why Millions of Senior Citizens Can’t Get Needed Medications

A new watchdog report says prescriptions are being rejected because doctors and insurers don’t communicate with each other.

Axios: Generic Prescription Drugs are Sometimes Inaccessible to Seniors

Plans providing Medicare’s prescription drug benefit are often slow to cover the first generic competition to a branded medication, according to a new white paper by the Association for Accessible Medicines.

Public’s View of Drug Companies Sinks to Record Low in Gallup Poll

The public’s favorability toward the pharmaceutical industry is at its lowest point since Gallup began polling the question in 2001.

Congress Must Act Now to Pave Way for More Affordable Prescription Drugs

The out-of-pocket costs required to successfully manage [chronic] conditions are forcing many patients to abandon treatments or forego other necessities such as food, shelter or transportation costs. Although biosimilar medications hold great promise for decreasing health care costs, congressional action is needed to increase competition for biosimilars and unlock their cost-savings potential.

Medicare Must Be Allowed to Negotiate Drug Prices

Four influential Democratic Senators delivered a message to their Republican colleagues and President Trump today:  allowing Medicare to negotiate directly with Big Pharma is the best way to bring down prescription drug prices.